# DISC-0974

Source: https://onco.cc/drugs/disc-0974/  
OnCo record `disc-0974` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DISC-0974 is an experimental monoclonal antibody from Disc Medicine, in phase 2 trials for myelofibrosis and myelodysplastic syndromes.

## Summary

DISC-0974 is a monoclonal antibody from Disc Medicine, with AbbVie as licensor. An antibody against hemojuvelin that suppresses hepcidin and so increases iron available for making red cells; in oncology it is tested for anaemia caused by myelofibrosis. Its furthest stage is phase 2, for myelofibrosis (anaemia of myelofibrosis) and myelodysplastic syndromes (registry only). ClinicalTrials.gov registers it in one study linked below. RALLY-MF phase 1/2 (NCT05320198) recruiting in myelofibrosis anaemia (registry also lists MDS). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DISC-0974
- Modality: Monoclonal antibody
- Mechanism: An antibody against hemojuvelin that suppresses hepcidin and so increases iron available for making red cells; in oncology it is tested for anaemia caused by myelofibrosis.

## Sources

- Disc Medicine: discmedicine.com: https://www.discmedicine.com/pipeline
- Disc Medicine: discmedicine.com: https://www.discmedicine.com/pipeline
- ClinicalTrials.gov: trials of DISC-0974: https://clinicaltrials.gov/search?intr=DISC-0974

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [Disc Medicine](https://onco.cc/companies/disc-medicine/)
- trials: [Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia](https://onco.cc/trials/nct05320198/)

---
JSON: https://onco.cc/api/v1/entities/disc-0974.json